PLIANT THERAPEUTICS

Company snapshot

Pliant Therapeutics is a clinical-stage biopharmaceutical company and leader in the discovery and development of integrin-based therapeutics. At Pliant, we share a commitment and a clear passion to drive innovative science towards addressing areas of unmet medical need. Together we believe we have the power to make a difference in the lives of patients. We believe that by harnessing the therapeuti

• 6 active pipeline program(s) linked via ClinicalTrials.gov.
• 13 US patent(s) indexed to this assignee profile.
• 6 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for PLIANT THERAPEUTICS. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for PLIANT THERAPEUTICS.

1. Jun 5, 2026 Clinical update

   Bexotegrast, Placebo matching PLN-74809 — Phase 3

2. Jun 5, 2026 Clinical update

   [18F]FP-R01-MG-F2 — Phase 1

3. May 26, 2026 Clinical update

   PLN-74809 — Phase 2

4. May 23, 2026 Clinical update

   PLN-74809 — Phase 2

5. May 23, 2026 Clinical update

   PLN-74809 — Phase 2

View all clinical trial activity →

• What is PLIANT THERAPEUTICS?

  Pliant Therapeutics is a pharma organization headquartered in South San Francisco, USA. It trades on NYSE under ticker PLRX. Primary therapeutic focus areas include Idiopathic Pulmonary Fibrosis, Idiopathic pulmonary fibrosis (IPF), Advanced or Metastatic Solid Tumor, Acute Respi

• Is PLIANT THERAPEUTICS publicly traded?

  Yes. PLIANT THERAPEUTICS is listed with ticker PLRX on NYSE per SEC EDGAR records linked on this profile.

• What drugs does PLIANT THERAPEUTICS develop or market?

  We link 3 drug profile(s) where PLIANT THERAPEUTICS is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/pliant-therapeutics-inc#company-drugs.

• What are the latest developments for PLIANT THERAPEUTICS?

  In the last 12 months our linked public records show 6 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does PLIANT THERAPEUTICS focus on?

  PLIANT THERAPEUTICS focuses on Idiopathic Pulmonary Fibrosis, Idiopathic pulmonary fibrosis (IPF), Advanced or Metastatic Solid Tumor based on our analysis of their pipeline programs and drug development activities.